



30th Annual Cancer Progress Conference May 7-8, 2019 Convене, 32 Old Slip, NYC

May 7, 2019

7:00 – 8:00am

Registration and Continental Breakfast

8:00 – 8:15am

Opening Remarks

Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

8:15 – 9:15am

Keynote: *Realizing the full potential of CRISPR for cancer therapies and other precision medicines*

Speaker: Rachel Haurwitz, PhD, Chief Executive Officer and Founder, Caribou Biosciences, Inc.

9:15 – 10:30am

Has the Time Come for Chemo-& Immuno-Prevention: Nixing the Nabobs of Negativity

Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

Panelists:

- John Letterio, MD, Division Chief, Pediatric Hematology and Oncology, UH Cleveland Medical Center Division Chief, Pediatric Hematology and Oncology, UH Rainbow Babies and Children's Hospital Professor, Pediatrics, CWRU School of Medicine Interim Director, UH Seidman Cancer Center
- Michael B. Sporn, MD, Professor of Pharmacology and Medicine/Molecular and Systems Biology/Active Emeritus, Dartmouth Medical School
- William C. Watt, PhD, President and Chief Executive Officer, EpiThany

10:30 – 11:00am

Networking Break

11:00 – 12:15pm

Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New

Moderator: Moderator: Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of Molecular Biology, Princeton University
- Tim van Hauwermeiren, MSc., MBA, Chief Executive Officer, arGEN-X
- Maurice Zauderer, PhD, President & Chief Executive Officer, Vaccinex, Inc.
- Chand Khanna, DVM, PhD, DACVP, Director, Vuja De Sciences
Chief Science Officer, Ethos Veterinary Health, President, Ethos Discovery Vuja De





12:15 – 1:30pm

Networking Luncheon & Keynote

Forward Thinking on the Future Oncology Biotech Supply Channel and Realities for Value Based Contracting

Speaker: Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.

1:30 – 2:45pm

Basket Trials Revisited: Faster, Better, Smarter Trials/Precision Medicine: Insights and Remaining Challenges, Perspectives from Academia, Pharma and Biotech

Moderator: Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Oncology & Dept. of Molecular & Experimental Medicine, Avera Cancer Institute

Panelists:

- Peter J. O'Dwyer, MD, Group Co-Chair, ECOG-ACRIN Cancer Research Group; Abramson Cancer Center, University of Pennsylvania
- Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology
- Gisela Schwab, President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis, Inc.

2:45 – 3:15pm

Networking Break

3:15 – 4:30pm

IO Session I: Combination Failures & Futures: Much Ado About What?

Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

Panelists

- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Ramy Ibrahim, MD, Vice President and Head of Research & Development, Parker Institute
- Robert Stein, MD, PhD, Senior R&D Advisor, Agenus
- Mai-Britt Zocca, MD, PhD, MBA, Chief Executive Officer, IO Biotech

5:00 – 7:00pm

Cancer Progress 2019 Reception

May 8, 2019

7:00 – 8:00am

Registration and Continental Breakfast

8:00 – 8:15am

Opening Remarks: Review of Day 1

Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health





8:15 – 9:30am

Payer/Access Panel

Moderator: Ed Saltzman, Executive Chairman, Cello Health BioConsulting, previously Defined Health

Panelists

- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Roger Longman, Chief Executive Officer, Real Endpoints
- Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.

9:30 – 10:45 am

IO Session II: IO Targets and Platforms - Target Versus Modality - What Are the Keys to the Kingdom?

Moderator: Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Ramy Ibrahim, MD, Vice President and Head of Research & Development, Parker Institute
- Louis Matis, MD, SVP and Chief Development Officer, Pieris Pharmaceuticals
- Dan Shoemaker, PhD, CSO, Fate Therapeutics

10:45 – 11:15am

Networking Break

11:15am – 12:30pm

Gynecological & Breast Cancers, Much Progress, Much to Do: How Novel Therapies from PARPs to Immunotherapies Are Transforming Care

Moderator: James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

Panelists

- Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Onc & Dept of Molecular & Experimental Medicine, Avera Cancer Institute
- Dmitriy Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
- Lajos Pusztai, MD, D Phil., Yale, Director Breast Cancer Translational Research
- Patrick Mahaffy, MD, President & CEO, Clovis Oncology

12:30 – 1:45pm

Biotech Deal-Making in the Face of IO Frenzy or Fatigue: Same Old or Different New?

Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

Panelists:





- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Jane Dancer, Chief Business Officer, F-star Biotech
- Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune
- Jean Chang, Vice President, Corporate Development & Oncology Project Lead, Dynavax

1:45 – 3:00pm

Networking Luncheon & Keynote

Speaker: Gregory C. Simon, President, Biden Cancer Initiative

3:00– 4:15pm

Insights from Heme Malignancies: Making Breakthrough Conventional and Unconventional Therapies Accessible Beyond Niche Blood Cancer Patients

Moderator: Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Adi Hoess, CEO, Affimed
- Lee Greenberger, VP and Chief Scientific Officer, The Leukemia & Lymphoma Society
- Dan Shoemaker, CSO, Fate Therapeutics
- Chris Bowden, MD, CMO, Agios

4:15 – 5:30pm

Oncology Innovation Powered by Investments and Competition from China

Moderator: James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

Panelists:

- Ji Li, PhD, Venture Partner, Lilly Asia Ventures
- Weimin Tang, PhD, Executive Vice President and Global Business Head, I-Mab Biopharma
- Garry Menzel, President and CEO, TCR² Therapeutics
- Jack Wu, PhD, Head of Business Development, Adlai Nortye

5:30 pm

Cancer Progress 2019 Conference Concludes